Patients undergoing four common elective procedures on the NHS are reporting significant health gains, according to annual data garnered from patient-reported outcome measures (PROMs).
News
NHS continues to miss key A&E, cancer targets
NHS performance data for June is again showing greater demand across both urgent and emergency care and elective areas, as well as the service’s continued failure to hit key waiting times and cancer targets.
NHS England launches consultation on HIV PrEP
NHS England has today launched a 45-day public consultation on a proposed clinical commissioning policy on Pre-Exposure Prophylaxis (PrEP) for HIV.
Lilly’s experimental breast cancer drug slips in trial
Lilly’s experimental breast cancer therapy abemaciclib has failed to hit interim efficacy targets in a late-stage combination trial, but the study will continue as planned on the recommendation of an independent data monitoring committee.
FDA nod for chemo nausea and vomiting drug
US regulators have approved a new, long-acting treatment to stave off acute and delayed chemotherapy-related nausea and vomiting.
AZ ups stake in Moderna
AstraZeneca has bumped up its stake in US biotech Moderna, which is pioneering the development of a new class of drugs made of messenger RNA, to nine percent.
A&E crisis in Lincolnshire
United Lincolnshire Hospitals NHS Trust is looking at reducing the opening hours of its emergency departments because of a “severe shortage” of available doctors that is putting patient safety at risk.
Takeda slams NICE’s preliminary Adcetris rejection
Takeda UK says it is disappointed that cost regulators have issued a negative recommendation for Cancer Drugs Fund therapy Adcetris in relapsed or refractory Hodgkin lymphoma.
Researchers find new info on ovarian cancer drug resistance
Research out of Dundee University has shed new light on how ovarian cancer becomes resistant to certain treatments.
Eisai, Biogen move Alzheimer’s drug into Phase III
Eisai and Biogen have had confirmation from US regulators that they can progress their BACE inhibitor E2609 into Phase III clinical trials to test its safety and efficacy in Alzheimer’s disease.
NICE u-turn in favour of Amgen’s novel melanoma drug
The National Institute for Health and Care Excellence is now recommending NHS use of Amgen’s Imlygic to treat advanced melanoma that has spread and can’t be surgically removed.
Six new drugs win funding nod for NHS Scotland
Treatment cost regulators for the NHS in Scotland have approved routine funding for six medicines, offering patients new treatment options for blood cancer, skin cancer, high cholesterol, diabetes, psoriatic arthritis, and infections in people with cystic fibrosis.
Experimental ALS drug wins EU orphan status
European regulators have assigned orphan drug status to an experimental therapy for Amyotrophic Lateral Sclerosis called masitinib, indicating that it has the potential to offer a significant benefit over existing treatment options.
Pfizer’s Vyndaqel slows neurodegenerative disease, analysis shows
A new analysis of data pooled from three clinical trials backs early intervention with Pfizer’s Vyndaqel in patients with the rare neurodegenerative disease transthyretin familial amyloid polyneuropathy (TTR-FAP).
Another late-stage trial failure for AZ’ selumetinib
AstraZeneca’s MEK 1/2 inhibitor selumetinib has suffered another blow after failing to hit targets in a late-stage trial assessing its safety and effectiveness alongside docetaxel in patients with a certain form of lung cancer.
